liu.seSearch for publications in DiVA
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Effects of IL-1β-Blocking Therapies in Type 2 Diabetes Mellitus: A Quantitative Systems Pharmacology Modeling Approach to Explore Underlying Mechanisms
Wolfram MathCore AB, Linköping, Sweden;.
Linköping University, Department of Clinical and Experimental Medicine, Division of Cell Biology. Linköping University, Faculty of Health Sciences. Wolfram MathCore AB, Linköping, Sweden;.
Department of Clinical Pharmacology, Drug Metabolism, and Pharmacokinetics, MedImmune, Cambridge, UK.
Bioscience, Astra Zeneca, Alderley Park, UK.
Show others and affiliations
2014 (English)In: CPT: pharmacometrics & systems pharmacology, ISSN 2163-8306, Vol. 3, no 6, 1-8 p.Article in journal (Refereed) Published
Abstract [en]

Recent clinical studies suggest sustained treatment effects of interleukin-1β (IL-1β)-blocking therapies in type 2 diabetes mellitus. The underlying mechanisms of these effects, however, remain underexplored. Using a quantitative systems pharmacology modeling approach, we combined ex vivo data of IL-1β effects on β-cell function and turnover with a disease progression model of the long-term interactions between insulin, glucose, and β-cell mass in type 2 diabetes mellitus. We then simulated treatment effects of the IL-1 receptor antagonist anakinra. The result was a substantial and partly sustained symptomatic improvement in β-cell function, and hence also in HbA1C, fasting plasma glucose, and proinsulin-insulin ratio, and a small increase in β-cell mass. We propose that improved β-cell function, rather than mass, is likely to explain the main IL-1β-blocking effects seen in current clinical data, but that improved β-cell mass might result in disease-modifying effects not clearly distinguishable until >1 year after treatment.

Place, publisher, year, edition, pages
2014. Vol. 3, no 6, 1-8 p.
National Category
Bioinformatics and Systems Biology
Identifiers
URN: urn:nbn:se:liu:diva-114549DOI: 10.1038/psp.2014.16PubMedID: 24918743Scopus ID: 2-s2.0-84903772139OAI: oai:DiVA.org:liu-114549DiVA: diva2:791044
Available from: 2015-02-26 Created: 2015-02-26 Last updated: 2015-08-10

Open Access in DiVA

fulltext(870 kB)143 downloads
File information
File name FULLTEXT01.pdfFile size 870 kBChecksum SHA-512
d00dbfcc558615271e02b7ec748330f4f8f4fdec3679885a631d9353e63dd5683b9d104e9143d73d84729898aab09b42db664fecf9de583317245d52e17d2b36
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMedScopus

Authority records BETA

Palmér, RobertNyman, ElinCedersund, Gunnar

Search in DiVA

By author/editor
Palmér, RobertNyman, ElinCedersund, Gunnar
By organisation
Division of Cell BiologyFaculty of Health SciencesDepartment of Biomedical EngineeringThe Institute of Technology
Bioinformatics and Systems Biology

Search outside of DiVA

GoogleGoogle Scholar
Total: 143 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 202 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf